CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway

Journal of Cellular Physiology

Volumn 211, Issue 1, 2007, Pages 112-120

  Jin, Caining ^b   Wang, Ying ^a   Han, Wenling ^a   Zhang, Yingmei ^b   He, Qihua ^a   Li, Dan ^b   Yin, Caihua ^b   Tian, Linjie ^b   Liu, Dazhen ^b   Song, Quanshen ^a   Ma, Dalong ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN CMTM8; REGULATOR PROTEIN; SERINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CMTM8 GENE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KNOCKOUT GENE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASES; CHEMOKINES; CYTOCHROMES C; ENZYME ACTIVATION; GENE EXPRESSION; HELA CELLS; HUMANS; MITOCHONDRIA; PHOSPHORYLATION; PHOSPHOSERINE; PLASMIDS; TRANSFECTION;

EID: 33847686805     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20914     Document Type: Article

References (37)

1. Arteaga CL, Johnson DH. 2001. Tyrosine kinase inhibitors-ZD 1839 (Iressa). Curr Opin Oncol 13:491-498.
2. Baselga J. 2002. Why the epidermal growth factor? The rationale for cancer therapy. The Oncologist 7:S2-S8.
3. Bienstock RJ, Barrett JC. 2001. KAII, A prostate metastasis suppressor: Prediction of solvated structure and interactions with binding partners; integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 32:139-153.
4. Bier H, Hoffmann T, Haas I, van Lierop A. 1998. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167-173.
5. Bonni A, Brunet A, West A, Datta S, Takasu M, Greenberg M. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358-1362.
6. Cande C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N, Kroemer G. 2002. Apoptosis-inducing factor (AIF): A novel caspase-independent death effector released from mitochondria. Biochimie 84:215-222.
7. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. 2002. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62:4307-4315.
8. Chen C, Yan J, Sun Q, Yao L, Jian Y, Lu J, Gu J. 2006. Induction of apoptosis by p110C requires mitochondrial translocation of the proapoptotic BCL-2 family member BAD. FEBS Lett 580:813-821.
9. Clavien PA, Rudiger HA, Selzner M. 2000. Mechanism of hepatocyte death after ischemia: Apoptosis versus necrosis. Int J Oncol 17:869-879.
10. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH. 2002. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277:27643-27650.
11. Goldstein NS, Armin M. 2001. Epidermal growth receptor factor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346.
12. Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, Gu W, Huang J, Gui L, Tang Y, Li F, Song Q, Di C, Wang L, Shi Q, Sun R, Xia D, Rui M, Tang J, Ma D. 2001. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 357:127-135.
13. Han W, Ding P, Xu M, Wang L, Rui M, Shi S, Liu Y, Zheng Y, Chen Y, Yang T, Ma D. 2003. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81:609-617.
14. Jin C, Ding P, Wang Y, Ma D. 2005. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett 579:6375-6382.
15. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257.
16. Lawrence TS, Nyati MK. 2002. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol 12:33-36.
17. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489.
18. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. 1996. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86:147-157.
19. Lynch DH, Yang XD. 2002. Therapeutic potential of ABX-EGF: A fully humanized anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29:47-50.
20. Mendelsohn J. 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703-2707.
21. Mimori K, Shiraishi T, Mashino K, Sonoda H, Yamashita K, Yoshinaga K, Masuda T, Utsunomiya T, Alonso MA, Inoue H, Mori M. 2003. MAL gene-expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 22:3463-3471.
22. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848.
23. Panka DJ, Wang W, Atkins MB, Mier JW. 2006. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66:1611-1619.
24. Pearse BM, Smith CJ, Owen DJ. 2000. Clathrin coat construction in endocytosis. Curr Opin Cell Biol 10:220-228.
25. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. 1999. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748.
26. Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. 2006. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 71:751-760.
27. Rishi AK, Zhang L, Yu Y, Jiang Y, Nautiyal J, Wali A, Fontana JA, Levi E, Majumdar AP. 2006. Cell cycle and apoptosis regulatory protein (CARP)-1 is involved in apoptosis signaling by epidermal growth factor receptor (EGFR). J Biol Chem 281:13188-13198.
28. Schoenfeld N, Bauer MKA, Grimm S. 2004. The metastasis suppressor gene C33/CD82/KA11 induces apoptosis through reactive oxygen intermediates I. FASEB J 18:158-160.
29. Vaupel P, Hockel M. 2001. Blood supply, oxygenation status and metabolic micromillieu of breast cancers: Characterization and therapeutic relevance. Hepatology 33:1555-1557.
30. Wang Y, Li X, Wang L, Ding P, Zhang Y, Han W, Ma D. 2004. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 117:1525-1532.
31. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. 1995. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905.
32. Yarden Y. 2001. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:53-58.
33. Zha J, Harada H, Yang E, Jockei J, Korsmeyer S. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628.
34. Zhang Y, Banerjee S, Wang ZW, Marciniak DJ, Majumdar AP, Sarkar FH. 2005. Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res 65:3877-3882.
35. Zhang Y, Banerjee S, Wang Z, Xu H, Zhang L, Mohammad R, Aboukameel A, Adsay NV, Che M, Abbruzzese JL, Majumdar AP, Sarkar FH. 2006. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res 66:1025-1032.
36. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413.
37. Zou H, Li Y, Liu X, Wang X. 1999. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274:11549-11556.